Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer

Published:2022-04 Issue:4 Volume:30 Page:1628-1644
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Han Wanting^ORCID,Liu Mingyu^ORCID,Han Dong^ORCID,Toure Anthia A.^ORCID,Li Muqing,Besschetnova Anna^ORCID,Wang Zifeng,Patalano Susan,Macoska Jill A.^ORCID,Lam Hung-Ming,Corey Eva^ORCID,He Housheng Hansen^ORCID,Gao Shuai^ORCID,Balk Steven P.,Cai Changmeng^ORCID

Funder

DOD

NCI

Terry Fox Foundation

CIHR INMD

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference71 articles.

1. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis;Yuan;Oncogene,2014

2. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1;Cai;Cancer Cell,2011